Skip to main content
OpenTrials
Completed

NCT Number: NCT04902781

Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia

This study is designed to assess the clinical benefit as well as the safety, pharmacokinetics (PK), and pharmacodynamics (PD) (reduction of galactitol levels) of AT-007 in pediatric subjects with Classic Galactosemia (CG).

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Children's Hospital Colorado, Aurora, Colorado, United States

Loading trial locations.

About this study

This is a randomized, double-blind, placebo-controlled study in pediatric subjects with CG. Children with CG ages 2 through 17 years will be enrolled. The study is designed to assess the clinical benefit using validated, standardized Clinical Outcome Assessments (COAs) as well as the safety, PK, and PD (reduction of galactitol levels) of AT-007 in pediatric subjects with CG. The study consists of 2 main parts, Part A and Part B, and an open-label extension (OLE).

Part A is an intra-patient dose escalation evaluating multiple ascending doses (MAD) of AT-007.

Part B is designed to assess the clinical benefits of long-term administration of AT-007 (at the optimum dose identified in Part A) on validated, standardized COAs.

Open-label extension (OLE) is an active treatment extension for patients who received placebo treatment in Part B.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion:

  • Male
  • Female non-pregnant
  • Female non-lactating subjects aged ≥2 to <18 years.
  • Diagnosis of Classic Galactosemia, confirmed by <1% GALT (galactose-1-phosphate uridyltransferase) enzyme activity in erythrocytes, or a historical record of diagnosis of <1% GALT enzyme activity.

Exclusion:

  • Male/Female with no significant health problems (other than classic Galactosemia)
  • No other disease that would preclude participation in the study.

Treatment and study plan

AT-007

Drug

Treatment with AT-007 given orally

Other names: aldose reductase inhibitor

Placebo

Other

Placebo given orally

Primary outcomes

  1. Global Statistical Test (GST)

    Time frame: Month 6, Month 12 and Month 18

    The primary endpoint is a GST of four components: 1) Behavioral Symptoms Index of the Behavioral Assessment Scale for Children 3 (BASC-3); 2) Activities of Daily Living from the BASC-3; 3) Oral Expression from the Oral and Written Language Skills-II (OWLS-II); 4) Listening Comprehension from the OWLS-II. Each individual component is also a secondary endpoint on their own with the test and scoring described below in the secondary endpoint section. For the GST, change from baseline using standardized z-scores is calculated for active versus placebo.

  2. Sensitivity Analysis of the Primary Endpoint (GST) with Cognition

    Time frame: Month 6, Month 12 and Month 18

    Sensitivity Analysis adding the National Institutes of Health Toolbox Cognition Battery (NIH-CB) test which measures cognition. NIH-CB is described below in the secondary endpoints. For the GST with cognition, change from baseline using standardized z-scores is calculated for active versus placebo.

  3. Sensitivity Analysis of the Primary Endpoint (GST) with Fine Motor Skills

    Time frame: Month 6, Month 12 and Month 18

    Sensitivity Analysis adding the National Institutes of Health Toolbox Motor Battery (NIH-MB) 9-Hole Pegboard test which measures fine motor skills. NIH-MB is described below in the secondary endpoints. For the GST with fine motor skills, change from baseline using standardized z-scores is calculated for active versus placebo.

Secondary outcomes

  1. Galactitol Level

    Time frame: Month 1, Month 2, Month 3, Month 6, Month 12, and Month 18

    The change from baseline in plasma galactitol (Pharmacodynamic measure)

  2. Behavioral Assessment System for Children-3 [Individual Components]

    Time frame: Month 6, Month 12 and Month 18

    Behavioral Assessment System for Children (BASC-3) has a normal range of 40-60 with the higher score showing more difficulty. There are multiple outcome scores included such as: Behavioral Symptoms Index, Activities of Daily Living, Withdrawal, Adapatability, Adaptive Skills, Socialization, and Functional Impairment Index.

  3. National Institute of Health Toolbox Cognition Battery

    Time frame: Month 6, Month 12 and Month 18

    Change from baseline in the NIH Toolbox Cognition Battery (NIH-CB). The NIH-CB uses multiple tests to evaluate Cognition and consists of tests of multiple constructs to yield individual ranking and demonstrate Cognitive Function Composite, Fluid Cognition Composite Sequence Memory, List Sorting, Pattern Comparison, and Crystallized Cognition Composite, Picture Vocabulary and Reading Recognition. This is standardized normal or 100 with a standard deviation of 10. Higher scores are better.

  4. Archimedes Spiral Drawing Test

    Time frame: Month 6, Month 12 and Month 18

    The Archimedes Spiral Drawing Test evaluates tremor on a scale of 0 (no tremor) to 4 (severe tremor).

  5. National Institute of Health Toolbox Motor Battery

    Time frame: Month 6, Month 12 and Month 18

    NIH Toolbox Motor Battery (NIH-MB) is a multiple of tests to determine fine motor skills using the 9-Hole Pegboard Test and gross motor skills using the Standing Balance Test. This is standardized normal or 100 with a standard deviation of 10. Higher scores are better.

  6. Scale for Assessment & Rating of Ataxia

    Time frame: Month 6, Month 12 and Month 18

    Scale for Assessment & Rating of Ataxia (SARA) is 0-40, the higher the score the worse value

  7. Oral and Written Language Scales-II

    Time frame: Month 6, Month 12 and Month 18

    Oral and Written Language Scales-II (OWLS-II) has both an Oral Expression and Listening Comprehension score. Scores are 0-100 with a standard deviation of 15.

  8. Rate of Lens Opacity

    Time frame: Month 6, Month 12 and Month 18

    Onset and severity/progression of cataracts using the Lens Opacity System (LOCS) III, has a grading scale of 1-4, with 4 the most severe as assessed by the reviewer per standard criteria for anterior and posterior obstruction of the eye.

  9. Sexual maturation in female patients as indicated by Tanner Stage

    Time frame: Month 6, Month 12 and Month 18

    Sexual maturation in female patients as indicated by Tanner Stage 1- 4 which is the ranking of physical development in children, adolescents and adults. This defines physical measurements of development based on external primary and secondary sex characteristics, such as the size of the breasts, and development of pubic hair. This is assessed by physical exam with Stage 1 per-pubescent and Stage 4 post pubescent.

  10. Ovarian function in female patients determined by hormonal tests.

    Time frame: Month 6, Month 12 and Month 18

    Ovarian function in female patients is recorded by hormonal measures: FSH (follicle stimulating hormone), estradiol, and LH (luteinizing hormone).

Other outcomes

  1. Biomarker Analysis [Exploratory]

    Time frame: Month 1, Month 2, Month 3, Month 6, Month 12, and Month 18

    This biomarker analysis will be performed to assess the levels of galactose and its other metabolites; Exploratory Endpoint

  2. Bayley Scales of Infant and Toddler Development-4 [Exploratory]

    Time frame: Month 6, Month 12 and Month 18

    Bayley Scales of Infant and Toddler Development (Bayley-4) showing a score of 40 -160 with higher values showing more development. Exploratory Endpoint

  3. Vineland Adaptive Behavior Scales-3 [Exploratory]

    Time frame: Month 6, Month 12 and Month 18

    Vineland Adaptive Behavior Scales (Vineland-3) has a normal score of 100 and lower scores show developmental delay; Exploratory Endpoint

Sponsors and collaborators

Lead sponsor

Applied Therapeutics, Inc.

Industry

Registry information

Official study title

A Sequential, Two-Part Study to Evaluate the Clinical Benefit, Safety, Pharmacokinetics, and Pharmacodynamics of AT-007 in Pediatric Patients With Classic Galactosemia (CG)

Important dates

Study start
2021
Primary completion
2023
Study completion
2025
First posted
May 26, 2021
Registry last updated
Oct 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.